佰仁医疗(688198) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 reached RMB 630.37 million, a year-on-year increase of 25.60%[3] - Operating profit increased by 45.78% to RMB 223.37 million, while total profit rose by 44.25% to RMB 217.51 million[9] - Net profit attributable to shareholders was RMB 200.19 million, reflecting a growth of 36.81% compared to the previous year[3] - The weighted average return on equity increased by 3.43 percentage points to 15.51%[3] - The net profit margin after excluding non-recurring gains was 30.69%, aligning with the company's expectations[8] - The net asset value per share increased to RMB 9.68, a rise of 6.14% from the previous year[3] Product Development - The company submitted 8 product registration applications and received approval for 3 new products during the reporting period[8] Asset Management - Total assets at the end of the reporting period were RMB 1,623.61 million, up 13.47% year-on-year[8] Market Segments - The structural heart disease segment grew by 26.07%, while the soft tissue repair segment increased by 24.23%[7] Expense Management - The company effectively controlled management and sales expenses while maintaining high R&D investment levels[8]